Literature DB >> 20661218

Restoration of the tumor suppressor p53 by downregulating cyclin B1 in human papillomavirus 16/18-infected cancer cells.

N N Kreis1, M Sanhaji, A Krämer, K Sommer, F Rödel, K Strebhardt, J Yuan.   

Abstract

Abrogation of functional p53 is responsible for malignant cell transformation and the maintenance of malignant state of human papillomavirus-infected cancer cells. Thus, restoration of p53 has been regarded as an important strategy for molecular intervention combating papillomavirus-associated malignancies. We show here that depleting cyclin B1 stabilizes and reactivates p53 in papillomavirus-infected cervical cancer cell lines HeLa and CaSki. HeLa cells depleted of cyclin B1 exhibit mitotic defects in spindle formation and chromosome alignment. Downregulation of cyclin B1 increases p14 alternative reading frame of p16, the positive regulator of p53, and decreases phosphorylation of Ser315 in p53. Whereas RO-3306, a selective inhibitor of cyclin-dependent kinase 1 (Cdk1), suppresses this phosphorylation at Ser315 of p53, ZM447439, targeting Aurora A/B kinases, shows no effect. Further analyses in HeLa cells and HCT116 p53(-/-) cells suggest that the Ser315 phosphorylation by Cdk1 regulates negatively the protein stability and the function of p53. Moreover, increased p53 in HeLa cells is functional by showing its increased downstream effectors p21, mouse double minute 2 and Bax. Restoration of p53 and silencing cyclin B1 render cervical carcinoma cells more susceptible to DNA damage agent camptothecin. Taken together, targeting cyclin B1 might be an attractive strategy for preventing and treating papillomavirus-associated cancer by reactivating p53 and by reducing the Cdk1 activity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20661218     DOI: 10.1038/onc.2010.290

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  27 in total

1.  Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo.

Authors:  Juping Yuan; Mourad Sanhaji; Andrea Krämer; Wolfgang Reindl; Matthias Hofmann; Nina-Naomi Kreis; Brigitte Zimmer; Thorsten Berg; Klaus Strebhardt
Journal:  Am J Pathol       Date:  2011-08-10       Impact factor: 4.307

2.  Functional analysis of phosphorylation of the mitotic centromere-associated kinesin by Aurora B kinase in human tumor cells.

Authors:  Andreas Ritter; Mourad Sanhaji; Alexandra Friemel; Susanne Roth; Udo Rolle; Frank Louwen; Juping Yuan
Journal:  Cell Cycle       Date:  2015-07-06       Impact factor: 4.534

3.  Deficiency of RITA results in multiple mitotic defects by affecting microtubule dynamics.

Authors:  K Steinhäuser; P Klöble; N-N Kreis; A Ritter; A Friemel; S Roth; J M Reichel; J Michaelis; M A Rieger; F Louwen; F Oswald; J Yuan
Journal:  Oncogene       Date:  2016-10-10       Impact factor: 9.867

4.  B-cell lymphoma 6 promotes proliferation and survival of trophoblastic cells.

Authors:  Cornelia Muschol-Steinmetz; Britta Jasmer; Nina-Naomi Kreis; Kerstin Steinhäuser; Andreas Ritter; Udo Rolle; Juping Yuan; Frank Louwen
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

5.  Chk1-induced CCNB1 overexpression promotes cell proliferation and tumor growth in human colorectal cancer.

Authors:  Yifeng Fang; Hong Yu; Xiao Liang; Junfen Xu; Xiujun Cai
Journal:  Cancer Biol Ther       Date:  2014-06-27       Impact factor: 4.742

6.  Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.

Authors:  Mourad Sanhaji; Frank Louwen; Brigitte Zimmer; Nina-Naomi Kreis; Susanne Roth; Juping Yuan
Journal:  Cell Cycle       Date:  2013-04-10       Impact factor: 4.534

7.  Live cell, image-based high-throughput screen to quantitate p53 stabilization and viability in human papillomavirus positive cancer cells.

Authors:  Gustavo Martínez-Noël; Valdimara Corrêa Vieira; Patricia Szajner; Erin M Lilienthal; Rebecca E Kramer; Kathleen A Boyland; Jennifer A Smith; Peter M Howley
Journal:  Virology       Date:  2021-05-22       Impact factor: 3.513

8.  Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors.

Authors:  Melanie Schwermer; Sangkyun Lee; Johannes Köster; Tom van Maerken; Harald Stephan; Angelika Eggert; Katharina Morik; Johannes H Schulte; Alexander Schramm
Journal:  Oncotarget       Date:  2015-06-20

9.  Induction of p53-independent growth inhibition in lung carcinoma cell A549 by gypenosides.

Authors:  Jung-Sen Liu; Tzu-Hsuan Chiang; Jinn-Shyan Wang; Li-Ju Lin; Wei-Chih Chao; Baskaran Stephen Inbaraj; Jyh-Feng Lu; Bing-Huei Chen
Journal:  J Cell Mol Med       Date:  2015-03-17       Impact factor: 5.310

10.  A novel class of inhibitors that target SRSF10 and promote p53-mediated cytotoxicity on human colorectal cancer cells.

Authors:  Muhammad Sohail; Lulzim Shkreta; Johanne Toutant; Safwat Rabea; Jean-Philippe Babeu; Caroline Huard; Jasmin Coulombe-Huntington; Aurélie Delannoy; Morgane Placet; Sameh Geha; Fernand-Pierre Gendron; François Boudreau; Mike Tyers; David S Grierson; Benoit Chabot
Journal:  NAR Cancer       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.